Published in Cancer Res on August 03, 2010
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut (2012) 2.40
DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene (2011) 1.76
miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS One (2011) 1.72
MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget (2013) 1.64
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
The role of microRNAs in colorectal cancer. Cancer J (2012) 1.44
A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol (2012) 1.42
Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis (2012) 1.32
Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res (2011) 1.27
The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One (2012) 1.26
Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. Clin Cancer Res (2011) 1.25
miR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig Dis Sci (2011) 1.24
miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS One (2013) 1.17
MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One (2012) 1.17
Differential expression of microRNAs in tumors from chronically inflamed or genetic (APC(Min/+)) models of colon cancer. PLoS One (2011) 1.16
Regulation of microRNAs by epigenetics and their interplay involved in cancer. J Exp Clin Cancer Res (2013) 1.14
Shielding the messenger (RNA): microRNA-based anticancer therapies. Pharmacol Ther (2011) 1.12
Tumor suppressive microRNA-137 negatively regulates Musashi-1 and colorectal cancer progression. Oncotarget (2015) 1.02
Epigenetic modifications in cardiovascular disease. Basic Res Cardiol (2012) 1.02
microRNAs: key triggers of neuronal cell fate. Front Cell Neurosci (2014) 1.02
Transcriptional targets of the schizophrenia risk gene MIR137. Transl Psychiatry (2014) 1.02
Temporal microRNA expression during in vitro myogenic progenitor cell proliferation and differentiation: regulation of proliferation by miR-682. Physiol Genomics (2010) 0.99
MiR-204 inhibits human NSCLC metastasis through suppression of NUAK1. Br J Cancer (2014) 0.96
Curcumin modulates DNA methylation in colorectal cancer cells. PLoS One (2013) 0.96
Potential Impact of miR-137 and Its Targets in Schizophrenia. Front Genet (2013) 0.96
Epigenetic changes in colorectal cancer. Chin J Cancer (2011) 0.94
Genetics and epigenetics of arrhythmia and heart failure. Front Genet (2013) 0.94
MicroRNA-10a is down-regulated by DNA methylation and functions as a tumor suppressor in gastric cancer cells. PLoS One (2014) 0.94
Dysregulation of microRNAs in colonic field carcinogenesis: implications for screening. PLoS One (2012) 0.93
Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. PLoS One (2012) 0.93
Transcriptional consequences of schizophrenia candidate miR-137 manipulation in human neural progenitor cells. Schizophr Res (2014) 0.92
microRNA-137 modulates pancreatic cancer cells tumor growth, invasion and sensitivity to chemotherapy. Int J Clin Exp Pathol (2014) 0.92
miR-137 regulates the constitutive androstane receptor and modulates doxorubicin sensitivity in parental and doxorubicin-resistant neuroblastoma cells. Oncogene (2013) 0.90
MiR-129-2 functions as a tumor suppressor in glioma cells by targeting HMGB1 and is down-regulated by DNA methylation. Mol Cell Biochem (2015) 0.89
MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer. Biomed Res Int (2015) 0.88
An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? Expert Rev Mol Diagn (2014) 0.87
MicroRNA library-based functional screening identified miR-137 as a suppresser of gastric cancer cell proliferation. J Cancer Res Clin Oncol (2014) 0.87
Genomic analyses reveal broad impact of miR-137 on genes associated with malignant transformation and neuronal differentiation in glioblastoma cells. PLoS One (2014) 0.86
Epigenetic field defects in progression to cancer. World J Gastrointest Oncol (2013) 0.86
miRNAs in precancerous lesions of the gastrointestinal tract. World J Gastroenterol (2011) 0.86
Growth inhibition of hepatocellular carcinoma tumor endothelial cells by miR-204-3p and underlying mechanism. World J Gastroenterol (2014) 0.85
Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications. Cell Death Dis (2012) 0.85
Epigenetic dysregulation in laryngeal squamous cell carcinoma. J Oncol (2012) 0.83
miRNA and vascular cell movement. Adv Drug Deliv Rev (2011) 0.82
IGFBP3 methylation is a novel diagnostic and predictive biomarker in colorectal cancer. PLoS One (2014) 0.82
Chemokine receptor CCR6 expression is regulated by miR-518a-5p in colorectal cancer cells. J Transl Med (2014) 0.81
Characterization of human gastric carcinoma-related methylation of 9 miR CpG islands and repression of their expressions in vitro and in vivo. BMC Cancer (2012) 0.81
MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators. Oncotarget (2015) 0.81
Nano-architectural alterations in mucus layer fecal colonocytes in field carcinogenesis: potential for screening. Cancer Prev Res (Phila) (2013) 0.80
MicroRNA Dysregulation in Colon Cancer Microenvironment Interactions: The Importance of Small Things in Metastases. Cancer Microenviron (2011) 0.80
FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. Bone Marrow Transplant (2014) 0.79
Identification of cancer mechanisms through computational systems modeling. Transl Cancer Res (2014) 0.79
MicroRNA-137 Contributes to Dampened Tumorigenesis in Human Gastric Cancer by Targeting AKT2. PLoS One (2015) 0.78
Field cancerisation in colorectal cancer: a new frontier or pastures past? World J Gastroenterol (2015) 0.77
The Roles of Two miRNAs in Regulating the Immune Response of Sea Cucumber. Genetics (2015) 0.77
Epigenetic analysis of microRNA genes in tumors from surgically resected lung cancer patients and association with survival. Mol Carcinog (2014) 0.77
Oncogenic miR-137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma. Am J Cancer Res (2016) 0.77
miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation. Mol Endocrinol (2015) 0.77
MicroRNA miR-J1-5p as a potential biomarker for JC virus infection in the gastrointestinal tract. PLoS One (2014) 0.77
MicroRNA Signatures of Colonic Polyps on Screening and Histology. Cancer Prev Res (Phila) (2016) 0.76
Promoter methylated microRNAs: potential therapeutic targets in gastric cancer. Mol Med Rep (2014) 0.76
Methylation kinetics and CpG-island methylator phenotype status in colorectal cancer cell lines. Biol Direct (2013) 0.76
The RNA-Binding Protein Musashi1: A Major Player in Intestinal Epithelium Renewal and Colon Cancer Development. Curr Colorectal Cancer Rep (2012) 0.76
A contrasting function for miR-137 in embryonic mammogenesis and adult breast carcinogenesis. Oncotarget (2015) 0.76
Reciprocal regulation between microRNAs and epigenetic machinery in colorectal cancer. Oncol Lett (2017) 0.75
Aberrant methylation-mediated silencing of microRNAs contributes to HPV-induced anchorage independence. Oncotarget (2016) 0.75
Epigenetic silencing of miR-137 contributes to early colorectal carcinogenesis by impaired Aurora-A inhibition. Oncotarget (2016) 0.75
miR-137 inhibits the proliferation of human non-small cell lung cancer cells by targeting SRC3. Oncol Lett (2017) 0.75
Mecp2-mediated Epigenetic Silencing of miR-137 Contributes to Colorectal Adenoma-Carcinoma Sequence and Tumor Progression via Relieving the Suppression of c-Met. Sci Rep (2017) 0.75
Association between hMLH1 hypermethylation and JC virus (JCV) infection in human colorectal cancer (CRC). Clin Epigenetics (2010) 0.75
MiR-137: an important player in neural development and neoplastic transformation. Mol Psychiatry (2016) 0.75
Epigenetic regulation of LSD1 during mammary carcinogenesis. Mol Cell Oncol (2014) 0.75
Single-molecule quantification of 5-hydroxymethylcytosine for diagnosis of blood and colon cancers. Clin Epigenetics (2017) 0.75
Epigenetic silencing of microRNA-137 enhances ASCT2 expression and tumor glutamine metabolism. Oncogenesis (2017) 0.75
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell (2004) 21.30
Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet (2009) 16.58
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res (2008) 8.97
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature (2005) 8.53
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med (2008) 5.91
Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res (2007) 5.62
MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst (2005) 5.22
The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation. Nat Genet (2008) 4.40
Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res (2008) 4.20
Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res (2008) 4.19
Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res (2008) 3.81
Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene (2009) 3.64
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res (2009) 2.65
Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer (2009) 2.62
Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues. J Mol Diagn (2008) 2.50
mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. Mol Cancer (2007) 2.40
MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res (2008) 2.38
Epigenetic silencing of the intronic microRNA hsa-miR-342 and its host gene EVL in colorectal cancer. Oncogene (2008) 2.26
CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle (2007) 2.12
Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes. Clin Cancer Res (2009) 1.87
Epigenetic field for cancerization. J Biochem Mol Biol (2007) 1.73
DNA methylation of microRNA genes in gastric mucosae of gastric cancer patients: its possible involvement in the formation of epigenetic field defect. Int J Cancer (2009) 1.66
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Microsatellite instability in colorectal cancer. Gastroenterology (2010) 7.39
Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. Gastroenterology (2004) 4.03
Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst (2013) 4.03
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Molecular classification and correlates in colorectal cancer. J Mol Diagn (2007) 3.25
Narrow-band imaging as an alternative to chromoendoscopy for the detection of dysplasia in long-standing inflammatory bowel disease: a prospective, randomized, crossover study. Gastrointest Endosc (2011) 2.96
Health benefits and cost-effectiveness of primary genetic screening for Lynch syndrome in the general population. Cancer Prev Res (Phila) (2010) 2.86
4E-binding protein 1: a key molecular "funnel factor" in human cancer with clinical implications. Cancer Res (2007) 2.67
The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology (2006) 2.63
Cutaneous manifestations of gastrointestinal disease: part I. J Am Acad Dermatol (2013) 2.58
Lynch syndrome: form, function, proteins, and basketball. Gastroenterology (2005) 2.57
Analysis of fecal DNA methylation to detect gastrointestinal neoplasia. J Natl Cancer Inst (2009) 2.57
β-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci U S A (2011) 2.45
MicroRNA-200c modulates epithelial-to-mesenchymal transition (EMT) in human colorectal cancer metastasis. Gut (2012) 2.40
Cutaneous manifestations of gastrointestinal disease: part II. J Am Acad Dermatol (2013) 2.38
An AIF orthologue regulates apoptosis in yeast. J Cell Biol (2004) 2.33
Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res (2003) 2.24
EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell Mol Life Sci (2012) 2.12
Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res (2004) 2.10
Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer (2003) 2.07
LIN28B promotes colon cancer progression and metastasis. Cancer Res (2011) 2.05
Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology (2008) 1.97
Epigenetic and genetic alterations in Netrin-1 receptors UNC5C and DCC in human colon cancer. Gastroenterology (2007) 1.82
Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res (2008) 1.81
Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev (2010) 1.74
Clinical uses of microsatellite instability testing in colorectal cancer: an ongoing challenge. J Clin Oncol (2007) 1.73
5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer. Gastroenterology (2010) 1.71
Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol (2002) 1.71
APC promoter hypermethylation contributes to the loss of APC expression in colorectal cancers with allelic loss on 5q. Cancer Biol Ther (2004) 1.71
Microsatellite instability and DNA mismatch repair protein deficiency in Lynch syndrome colorectal polyps. Cancer Prev Res (Phila) (2012) 1.65
Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol (2010) 1.63
Epigenetics of colorectal cancer. Gastroenterology (2012) 1.60
Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet (2006) 1.59
Evaluation of microsatellite instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biol Ther (2004) 1.57
Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol (2003) 1.55
Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg (2014) 1.46
Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology (2010) 1.46
PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol (2007) 1.44
Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer. Gastroenterology (2008) 1.43
Molecular pathogenesis of colorectal cancer: implications for molecular diagnosis. Cancer (2005) 1.42
A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin Cancer Res (2003) 1.41
Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer (2011) 1.39
Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review. Curr Genomics (2011) 1.39
Aurora-A expression is independently associated with chromosomal instability in colorectal cancer. Neoplasia (2009) 1.39
Association of JC virus T-antigen expression with the methylator phenotype in sporadic colorectal cancers. Gastroenterology (2006) 1.38
Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology (2012) 1.37
Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis. Gut (2013) 1.37
A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. Phytother Res (2012) 1.34
Microsatellite instability and suppressed DNA repair enzyme expression in rheumatoid arthritis. J Immunol (2003) 1.32
Comparative analysis of chloroplast genomes: functional annotation, genome-based phylogeny, and deduced evolutionary patterns. Genome Res (2002) 1.32
Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer (2002) 1.32
Endometrial carcinoma: pathology and genetics. Pathology (2007) 1.32
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab. J Clin Oncol (2013) 1.32
High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther (2007) 1.30
A genetically engineered oncolytic adenovirus decoys and lethally traps quiescent cancer stem-like cells in S/G2/M phases. Clin Cancer Res (2013) 1.29
Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol (2009) 1.28
Epigenetic changes induced by curcumin and other natural compounds. Genes Nutr (2011) 1.28
Structure and function of the components of the human DNA mismatch repair system. Int J Cancer (2006) 1.28
Colorectal cancers with microsatellite instability display unique miRNA profiles. Clin Cancer Res (2011) 1.27
Impact of BRAF, MLH1 on the incidence of microsatellite instability high colorectal cancer in populations based study. Mol Cancer (2008) 1.27
Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer (2005) 1.26
Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res (2011) 1.26
The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One (2012) 1.26